Medically reviewed by
Betsy Greenleaf, DO
Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging Low libido in women — a persistent lack of interest in sexual activity — is among the most frequent sexual health complaints clinicians encounter, yet it is consistently underreported because of embarrassment and the lingering taboo around discussing sexual concerns. When that low desire is persistent and, critically, when it causes the woman distress, it meets the clinical definition of hypoactive sexual desire disorder (HSDD). This guide situates HSDD within the broader field of female sexual dysfunction and is written for clinicians who want an accurate, respectful overview.
It is clinical education, not medical advice, and nothing here is a treatment recommendation, protocol, or substitute for a thorough individual evaluation. As Empire faculty member Dr. Betsy Greenleaf frames it: sexual dysfunction is usually the symptom of a larger problem, and our job is to look at the roots under the leaves of the tree rather than reaching for a single fix.
What is low libido in women?
Clinically, low libido in women is described as a persistent or recurrent deficiency or absence of sexual desire. Under the diagnostic criteria, a woman is generally experiencing several of a recognizable cluster: little or no desire for any sexual activity, few or no sexual thoughts or fantasies, reluctance to initiate, reduced pleasure during activity, diminished interest in a partner's sexual or erotic cues, and few or no physical sensations during sexual activity.
The single most important qualifier is distress. A diagnosis of HSDD under the DSM-5 requires that the low desire cause clinically significant personal distress or interpersonal difficulty. This distinction matters in practice: many women have lower desire than a partner or than they once did and feel perfectly fine about it — that is a variation, not a disorder. A related but distinct scenario is a mismatch between a woman's desire and her partner's, which can generate conflict and dissatisfaction without either person being abnormal. Naming these distinctions accurately, and without judgment, is the first clinical task.
How common is it?
Low desire is common, and it becomes more common with age and hormonal transition. Across studies, an estimated 43% of women experience some form of sexual dysfunction, and these figures are widely regarded as underreported given how reluctant patients are to raise the subject. For low libido specifically, prevalence in menopausal women has been reported to range roughly from 27% to 52%, with the highest rates — around 52% — seen in women who have undergone surgical menopause.
Prevalence also tracks with overall health. Low libido has been reported in roughly 38% of women with metabolic disorders versus about 19% of healthy controls, and rates climb further in populations with conditions such as advanced kidney disease. The practical takeaway is that low desire frequently travels with metabolic and systemic illness, which is exactly why a whole-body assessment matters more than a narrow genital one.
What causes low libido in women?
Low libido is almost always multifactorial. Rather than a single lesion, clinicians are usually looking at several overlapping contributors:
- Hormonal. Declining estrogen at menopause can produce vaginal dryness and pain that secondarily suppress desire, while testosterone contributes to desire itself. Hormonal contraceptives can also blunt libido in some women.
- Psychological. Depression, anxiety, chronic stress, body image, and past trauma all weigh heavily on desire. For women in particular, how a woman feels about herself, her life, her partner, and her relationship strongly shapes her sexual response.
- Relational. Familiarity and routine in long-term relationships can quiet the dopamine-driven novelty that fuels early passion — a normal trajectory rather than a pathology.
- Medications. SSRIs are a frequent and underappreciated culprit, and many other drugs affect desire and arousal.
Underpinning all of these is the desire–arousal interplay. The older, linear Masters and Johnson model placed desire first, followed by arousal. The Basson model is a better representation of much of female sexuality: arousal can precede desire. Many women, especially in long-term relationships, do not begin an encounter with spontaneous desire; instead, being receptive to intimacy allows psychological arousal and pelvic blood flow to build, and desire follows. Dr. Greenleaf notes that explaining this model to patients frequently eases the anxiety around sex that itself suppresses desire. The clinical relevance is direct: a woman who waits for spontaneous desire that rarely comes may interpret a normal pattern as dysfunction.
The hormone connection
Hormones are a genuine lever in female desire, and three deserve specific attention. Estrogen maintains vaginal tissue health; its decline at menopause drives dryness and dyspareunia that can secondarily collapse desire even when desire itself is intact. Testosterone — present and physiologically important in women, not just men — contributes to desire more directly, and low levels are one input clinicians evaluate. DHEA, an adrenal precursor to both estrogen and testosterone, has been studied in vaginal formulations and shown to improve aspects of sexual function including desire, arousal, and lubrication, with hormone levels generally staying within normal postmenopausal ranges.
Two cautions keep this honest. First, the relationship between measured hormone levels and symptoms is loose: many women with low testosterone report normal desire, and many women with low desire have normal testosterone. Hormones are one input, not the verdict. Second, and emphatically: hormones are a tool, not the answer. As Dr. Greenleaf puts it, even with hormone therapy, if stress is not addressed, hormones will not help. For the mechanistic detail of how estrogen, testosterone, and DHEA shape the sexual response, see our companion guide on hormones and sexual function, and for the broader treatment framework, our cluster on hormone replacement therapy. The specific agents, dosing strategies, and monitoring belong to individualized care and are taught in Empire's courses rather than reproduced here.
Treatment options
Because the cause is layered, effective treatment is layered too. The foundational principle from the lecture is blunt and worth repeating to patients: there is no “horny pill,” because the brain is the most important sex organ. Many patients assume a PDE5 inhibitor like Viagra will restore desire; it affects blood flow and will not work without brain stimulation. Treatment therefore starts upstream.
Address the foundations
Correct contributing hormonal deficits where appropriate; review and, where possible, adjust offending medications such as SSRIs or libido-blunting contraceptives; and target the modifiable lifestyle drivers — sleep, physical activity, and above all stress. Stress is the biggest suppressor of libido: when the sympathetic “fight-or-flight” nervous system is engaged, blood flow and energy are shunted away from the “rest, digest, and reproduce” functions the parasympathetic system governs. Sex and stress cannot coexist, which is why stress reduction is not a soft add-on but central to treatment.
FDA-approved pharmacologic options
For premenopausal women with acquired, generalized HSDD, two non-hormonal agents are FDA-approved. Flibanserin is a daily oral medication thought to modulate the balance of serotonin, dopamine, and norepinephrine in the brain; it carries notable counseling points, including taking it at bedtime and avoiding alcohol around dosing because of the risk of low blood pressure and fainting. Bremelanotide is a melanocortin receptor agonist given by subcutaneous injection before anticipated activity. Both produce modest improvements in desire and related distress in clinical trials — an honest and important framing for patients, since neither is a cure. The peptide PT-141 (bremelanotide) is the same melanocortin-pathway molecule; in women, the FDA-approved form is the indication described above, and its use in this space is discussed in depth in our peptide cluster.
Therapy and counseling
Psychological and relational interventions are frequently part of the plan rather than an afterthought. Cognitive behavioral therapy, mindfulness-based approaches that improve sexual awareness and responsiveness, and referral to a sex therapist or counselor all have a role — particularly given how heavily stress, anxiety, and relationship dynamics weigh on female desire. The specific protocols, agent selection, and how to combine these modalities are taught in Empire's course.
The biopsychosocial approach
The thread running through everything above is that female low libido is rarely solved by a single intervention. A useful clinical model is biopsychosocial: the biological (hormones, medications, metabolic and systemic illness, vaginal tissue health), the psychological (stress, mood, anxiety, body image, trauma, and the anxiety that surrounds sex itself), and the social and relational (partnership dynamics, novelty, communication, and life demands). Pull on only one strand and the result usually disappoints — the hormone replacement that fails because stress was never addressed is the classic example.
This is also why the evaluation matters as much as the treatment. A thorough sexual history taken in a trusting, non-judgmental, confidential setting; a whole-body medical review that looks beyond the pelvis to thyroid, metabolic, and psychological contributors; appropriate laboratory assessment of relevant hormones; and validated instruments such as the Female Sexual Function Index together build the picture that treatment then addresses. Done well, this is a respectful, methodical clinical workup — not a prescription pad reflex.
Provider training
Female low libido sits at the intersection of endocrinology, psychology, and relationship dynamics, which is exactly what makes it challenging — and what makes structured education valuable. Providers who treat it well are fluent in taking a sexual history comfortably, in distinguishing HSDD from low desire without distress, in the hormonal and neurochemical drivers of female desire, and in the evidence behind each pharmacologic and procedural option. They also know where the evidence is strong and where it is merely emerging.
Empire Medical Training teaches this material as part of a physician-led course on sexual health and dysfunction, taught by Dr. Betsy Greenleaf — the first board-certified female gynecologist in the United States and Empire's Director of Anti-Aging. The course moves from the physiology of the female sexual response through assessment, the hormonal and pharmacologic toolkit, and the practical judgment needed to apply it responsibly in practice.
Train to treat female sexual dysfunction
Empire Medical Training's sexual health and dysfunction course covers the assessment and management of female low libido, HSDD, the hormonal toolkit, and FDA-approved and emerging therapies — taught by board-certified physician faculty. Build the competence and confidence to offer this care in your practice.
Explore the Sexual Health Course →
Claim Your Prize!